The case for a new measurement of HIV treatment success; PrEP and HIV incidence in Australia; benefits of moderate exercise among older people with HIV; CD4 recovery rates after long-term viral suppression.
Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.
How food insecurity feeds inflammation; racial disparities in HPV16 prevalence; how HIV meds affect pre-existing neurocognitive impairment; central nervous system inflammation in the setting of HIV treatment success.
Among this week's selection of four studies, we learn about data from a large study exploring the relative durability of first-line antiretroviral regimens stratified by drug class. (Spoiler alert: Older protease inhibitors don't do so well.)
Sobering data regarding linkage to HIV care among women in the U.S.; Latinx HIV incidence inequalities; efficacy of hepatitis C treatment among people with HIV; and a call for frequent STI testing among at-risk people with HIV.
Among our featured reports this week, we learn about how the vaginal microbiome may affect antiretroviral concentrations in the genital tract, and we look at the potential impact of global supply-chain interruptions on HIV drug resistance.
"When it comes to persistent low-level viremia in treated HIV patients, there's much agony, gnashing of teeth and confusion," Paul Sax, M.D. writes.
Among our four featured reports this week, we learn about the critical intersection between HIV treatment access and reduced HIV incidence in the U.S. -- and about the value of replacing placebos with PrEP in clinical trials on HIV prevention.
Among four noteworthy studies we highlight this week is a new addition to the vast mountain of evidence tying lung cancer risk to smoking -- but with an HIV-specific twist, and a caldera of hope for those who quit.
Among this week's collection of four study summaries are data indicating that reducing U.S. foreign aid for HIV-fighting efforts is a really bad idea, no matter which way you cut it.